| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1006168749 |
| P356 | DOI | 10.1186/1471-2334-8-67 |
| P932 | PMC publication ID | 2409345 |
| P698 | PubMed publication ID | 18485230 |
| P5875 | ResearchGate publication ID | 5365807 |
| P50 | author | Jean-Damien Ricard | Q88687353 |
| P2093 | author name string | Didier Dreyfuss | |
| Roman Mounier | |||
| Guillaume Chevrel | |||
| Agnès Meybeck | |||
| Guilène Barnaud | |||
| Mathieu Eveillard | |||
| P2860 | cites work | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
| A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study | Q29615430 | ||
| The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination | Q29617876 | ||
| Assessment of coma and impaired consciousness. A practical scale | Q29618624 | ||
| Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome | Q33803393 | ||
| Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group | Q33980144 | ||
| 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer | Q34114674 | ||
| Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. | Q34155402 | ||
| Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamic considerations | Q36127620 | ||
| Treatment of bacterial urinary tract infections: presence and future | Q36368679 | ||
| Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia | Q39608037 | ||
| Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. | Q40558538 | ||
| Exposure to co-amoxiclav as a risk factor for co-amoxiclav-resistant Escherichia coli urinary tract infection | Q43716737 | ||
| Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. | Q43751593 | ||
| Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms | Q43933887 | ||
| Susceptibility of Enterobacteriaceae to beta-lactam agents and fluoroquinolones: a 3-year survey in France. | Q44016374 | ||
| Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia | Q44357095 | ||
| Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes | Q44436393 | ||
| Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: a clinical study | Q44458237 | ||
| Antibiotic resistance rates and phenotypes among isolates of Enterobacteriaceae in French extra-hospital practice | Q44778046 | ||
| Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy | Q46687276 | ||
| Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment | Q46851716 | ||
| Prognosis in acute organ-system failure. | Q53762948 | ||
| Emergence of piperacillin/tazobactam-resistant Escherichia coli. | Q54026065 | ||
| Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. | Q54452583 | ||
| Sepsis in European intensive care units: results of the SOAP study. | Q54471944 | ||
| [Antibiotic resistance: from the results of ONERBA's networks to good antibiotic use]. | Q54479590 | ||
| Characterization of intensive care unit patients using a model based on the presence or absence of organ dysfunctions and/or infection: the ODIN model | Q72789666 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | piperacillin/tazobactam | Q7197337 |
| Escherichia coli | Q25419 | ||
| P304 | page(s) | 67 | |
| P577 | publication date | 2008-05-17 | |
| P1433 | published in | BMC Infectious Diseases | Q15759919 |
| P1476 | title | Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study | |
| P478 | volume | 8 |
| Q35306037 | Co-existence of beta-lactamases in clinical isolates of Escherichia coli from Kathmandu, Nepal |
| Q37630039 | Management of Pneumonia and Blood Stream Infections with New Antibiotic Adjuvant Entity (Ceftriaxone + Sulbactam + Disodium Edetate)- A Novel Way to Spare Carbapenems |
| Q54326043 | Pathophysiology of Escherichia coli ventilator-associated pneumonia: implication of highly virulent extraintestinal pathogenic strains. |
Search more.